: Pulmonary Hypertension (PH) is a complex cardiovascular disorder characterized by elevated blood pressure in the pulmonary arteries. Current therapeutic approaches for PH have limitations in addressing the underlying molecular mechanisms. This article explores the potential of noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), delivered through Lipid-Based Nanoparticles (LNPs) as a novel treatment strategy. These ncRNAs play critical roles in regulating vascular function and are implicated in PH pathogenesis. LNPs provide a promising method for the efficient and targeted delivery of ncRNAs. Advances in LNP technology, including the incorporation of R8 peptide modification, have shown promise in enhancing the delivery and efficacy of ncRNAs in PH models. Challenges such as biocompatibility, toxicity, and precise targeting must be addressed as these therapies move toward clinical application. The potential of personalized medicine and the integration of artificial intelligence in LNP design are discussed as prospects. In conclusion, ncRNA lipotherapeutics delivered via LNPs offer a transformative approach to treating PH, potentially leading to more effective management and improved patient outcomes in the future. However, continued research and clinical trials are necessary to fully realize their therapeutic potential in the field of PH treatment.

中文翻译：

---

非编码 RNA 脂质治疗：肺动脉高压治疗的一个有希望的突破

：肺动脉高压（PH）是一种复杂的心血管疾病，其特征是肺动脉血压升高。目前 PH 的治疗方法在解决潜在的分子机制方面存在局限性。本文探讨了通过脂质纳米颗粒 (LNP) 传递的非编码 RNA (ncRNA) 作为一种新型治疗策略的潜力，包括 microRNA (miRNA)、长非编码 RNA (lncRNA) 和环状 RNA (circRNA)。这些 ncRNA 在调节血管功能中发挥着关键作用，并与 PH 发病机制有关。 LNP 为 ncRNA 的高效和靶向递送提供了一种有前途的方法。 LNP 技术的进步，包括 R8 肽修饰的结合，已显示出在增强 PH 模型中 ncRNA 的递送和功效方面的前景。随着这些疗法走向临床应用，必须解决生物相容性、毒性和精确靶向等挑战。个性化医疗的潜力以及人工智能在 LNP 设计中的集成进行了展望。总之，通过 LNP 提供的 ncRNA 脂质治疗为治疗 PH 提供了一种变革性的方法，有可能在未来带来更有效的管理并改善患者的治疗结果。然而，需要继续研究和临床试验才能充分发挥其在 PH 治疗领域的治疗潜力。